(MLAB) Mesa Laboratories - Overview
Sector: Technology | Industry: Scientific & Technical Instruments | Exchange: NASDAQ (USA) | Market Cap: 502m USD | Total Return: -1.6% in 12m
Avg Turnover: 15.3M
EPS Trend: -36.6%
Qual. Beats: 0
Rev. Trend: 95.2%
Qual. Beats: 0
Warnings
P/E ratio 75.0
Tailwinds
Idiosyncratic Leader
Mesa Laboratories, Inc. (MLAB) is a life sciences tools provider focused on quality control and precision diagnostics. The company operates across four primary segments: Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Its portfolio includes biological indicators, genetic analysis systems, automated protein analysis hardware, and environmental monitoring instruments used primarily in the pharmaceutical, healthcare, and medical device sectors.
The company utilizes a razor-and-blade business model, where the installation of proprietary hardware-such as the MassARRAY and Gyrolab systems-drives recurring revenue through the sale of specialized consumables, reagents, and maintenance services. This structure is common in the Life Sciences Tools & Services sector, as it creates high switching costs for laboratory customers once a platform is integrated into their workflows. Mesas expansion into clinical genomics and peptide synthesis reflects a strategic pivot toward high-growth biotechnology applications beyond its traditional industrial calibration roots.
For a deeper look into the companys valuation metrics and historical performance, consider reviewing the detailed data available on ValueRay.
- Sterilization segment demand driven by pharmaceutical and medical device manufacturing volume
- Clinical Genomics revenue fluctuates with genetic testing and pharmacogenetics adoption rates
- Biopharmaceutical drug development spending impacts protein analysis and peptide synthesis sales
- Calibration solutions growth depends on healthcare facility and laboratory regulatory compliance
- Acquisition integration success and debt leverage levels influence overall shareholder valuation
| Net Income: 6.71m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -1.11 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA 0.10 > 3% & CFO 41.5m > Net Income 6.71m |
| Net Debt (154.1m) to EBITDA (43.5m): 3.54 < 3 |
| Current Ratio: error (cannot be calculated; needs correct Total Current Assets and Liabilities) |
| Outstanding Shares: last quarter (5.54m) vs 12m ago 2.12% < -2% |
| Gross Margin: 63.53% > 18% (prev 0.63%; Δ 6.29k% > 0.5%) |
| Asset Turnover: 57.86% > 50% (prev 55.61%; Δ 2.26% > 0%) |
| Interest Coverage Ratio: 2.29 > 6 (EBITDA TTM 43.5m / Interest Expense TTM 8.10m) |
As of May 31, 2026, the stock is trading at USD 102.02 with a total of 284,839 shares traded.
Over the past week, the price has changed by -6.35%,
over one month by +6.70%,
over three months by +5.81% and
over the past year by -1.61%.
Mesa Laboratories has received a consensus analysts rating of 3.50. Therefore, it is recommended to hold MLAB.
- StrongBuy: 2
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 104.5 | 2.4% |
P/E Trailing = 75.0413
P/E Forward = 35.2113
P/S = 2.0136
P/B = 2.6935
Revenue TTM = 249.1m USD
EBIT TTM = 18.5m USD
EBITDA TTM = 43.5m USD
Long Term Debt = 161.0m USD (from longTermDebt, two quarters ago)
Short Term Debt = 5.16m USD (from shortTermDebt, two quarters ago)
Debt = 181.0m USD (corrected: LT Debt 161.0m + ST Debt 5.16m) + Leases 14.9m
Net Debt = 154.1m USD (calculated: Debt 181.0m - CCE 26.9m)
Enterprise Value = 655.7m USD (501.7m + Debt 181.0m - CCE 26.9m)
Interest Coverage Ratio = 2.29 (Ebit TTM 18.5m / Interest Expense TTM 8.10m)
EV/FCF = 17.40x (Enterprise Value 655.7m / FCF TTM 37.7m)
FCF Yield = 5.75% (FCF TTM 37.7m / Enterprise Value 655.7m)
FCF Margin = 15.13% (FCF TTM 37.7m / Revenue TTM 249.1m)
Net Margin = 2.69% (Net Income TTM 6.71m / Revenue TTM 249.1m)
Gross Margin = 63.53% ((Revenue TTM 249.1m - Cost of Revenue TTM 90.9m) / Revenue TTM)
Gross Margin QoQ = 73.21% (prev 64.18%)
Tobins Q-Ratio = 1.53 (Enterprise Value 655.7m / Total Assets 427.7m)
Interest Expense / Debt = 4.47% (Interest Expense 8.10m / Debt 181.0m)
Taxrate = 44.13% (5.30m / 12.0m)
NOPAT = 10.3m (EBIT 18.5m * (1 - 44.13%))
Current Ratio = unknown (Total Current Assets 106.3m / Total Current Liabilities none)
Debt / Equity = 0.97 (Debt 181.0m / totalStockholderEquity, two quarters ago 186.7m)
Debt / EBITDA = 3.54 (Net Debt 154.1m / EBITDA 43.5m)
Debt / FCF = 4.09 (Net Debt 154.1m / FCF TTM 37.7m)
Total Stockholder Equity = 174.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.56% (Net Income 6.71m / Total Assets 427.7m)
RoE = 3.85% (Net Income TTM 6.71m / Total Stockholder Equity 174.4m)
RoCE = 5.52% (EBIT 18.5m / Capital Employed (Equity 174.4m + L.T.Debt 161.0m))
RoIC = unknown (NOPAT 10.3m, Invested Capital 0.0, EBIT 18.5m)
WACC = 7.99% (E(501.7m)/V(682.6m) * Re(9.97%) + D(181.0m)/V(682.6m) * Rd(4.47%) * (1-Tc(0.44)))
Discount Rate = 9.97% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 71.91 | Cagr: 1.21%
[DCF] Terminal Value 73.57% ; FCFF base≈39.8m ; Y1≈35.8m ; Y5≈30.5m
[DCF] Fair Price = 60.08 (EV 486.0m - Net Debt 154.1m = Equity 331.9m / Shares 5.52m; r=8.35% [WACC [floored]]; 5y FCF grow -12.34% → 2.50% )
EPS Correlation: -36.60 | EPS CAGR: -13.20% | SUE: 0.34 | # QB: 0
Revenue Correlation: 95.19 | Revenue CAGR: 6.58% | SUE: -0.82 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.06 | Chg30d=-31.61% | Revisions=-20% | Analysts=1
EPS next Quarter (2026-09-30): EPS=1.26 | Chg30d=-17.11% | Revisions=-20% | Analysts=1
EPS current Year (2027-03-31): EPS=5.39 | Chg30d=-11.06% | Revisions=-20% | GrowthEPS=-35.4% | GrowthRev=+5.6%